According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL (605177.SH) announced that the company aims to further enhance and improve its overall industrial development layout and strengthen the competitiveness of its existing pharmaceutical industry pipeline. It will invest RMB 60 million with its own funds to establish a wholly-owned subsidiary, Zhejiang Shan Heng Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhejiang Shan Heng"), in Sanmen County, Zhejiang Province, accounting for 100% of Zhejiang Shan Heng's registered capital. The establishment of this wholly-owned subsidiary will help enrich the industrial pipeline, enhance overall competitiveness, and seek business expansion opportunities. Recently, Zhejiang Shan Heng completed the industrial and commercial registration procedures and obtained the "Business License" issued by the Sanmen County Market Supervision Administration.

The company is continuously enriching its product pipeline around the medium- and long-term development strategy of "focusing on active pharmaceutical ingredients, extending forward and backward." The investment in establishing the wholly-owned subsidiary Zhejiang Shan Heng in Sanmen County, Zhejiang Province, to build a comprehensive production base for the health industry aligns with the company's strategic planning and business development needs. The establishment of Zhejiang Shan Heng and its future smooth implementation will benefit the company by enriching its product structure, empowering the overall development of the company, and aligning with the long-term development plan and the interests of all shareholders